FOLR1 and carcinoma: PDX #105 and #233 both had mixed composition: for PDX #105, FRA expression was mainly observed in the carcinoma component (47% FRA+), for PDX #233 although predominantly carcinomatous in appearance, it had < 1% FRA positivity (Figure 1C, Table S4).